^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thrombopoietin receptor agonist

    Related drugs:
    1d
    The Use of Eltrombopag Post HSCT in BMFD (clinicaltrials.gov)
    P2/3, N=118, Completed, The First Affiliated Hospital of Soochow University | Recruiting --> Completed | Trial completion date: Jul 2027 --> Oct 2025
    Trial completion • Trial completion date
    |
    Promacta (eltrombopag)
    3d
    Eltrombopag olamine induces apoptosis in human breast adenocarcinoma and hepatocellular carcinoma cells through modulation of multiple apoptotic pathways. (PubMed, Sci Rep)
    Interactions of Eltrombopag with EGFR, FAS, p53, and TNFα proteins were detected through molecular docking simulations. These findings highlight the potential of Eltrombopag olamine as a repurposed, multi-targeted therapeutic candidate for the treatment of breast and liver cancer.
    Journal • PARP Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MAPK1 (Mitogen-activated protein kinase 1) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • ANXA5 (Annexin A5)
    |
    EGFR expression
    |
    Promacta (eltrombopag)
    3d
    Herombopag Treated T-DM1 Induced Platelet Reduction (clinicaltrials.gov)
    P2, N=56, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P2 trial
    |
    Kadcyla (ado-trastuzumab emtansine)
    4d
    Effect of Thrombopoietin Receptor Agonist Romiplostim on the Ionizing Radiation-Induced Premature Aging. (PubMed, Pharmacol Res Perspect)
    Although bone marrow cell recovery was incomplete, spleen cell counts were significantly restored (2-fold) by 50 μg/kg RP, and SA-β-gal activity, a marker of cellular senescence, was also significantly suppressed by approximately 15%. These findings suggest that RP may partially ameliorate radiation-induced premature aging, providing a basis for future research addressing health issues associated with aging and radiation exposure.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
    |
    Nplate (romiplostim)
    9d
    A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial
    |
    cisplatin • gemcitabine
    13d
    Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study (clinicaltrials.gov)
    P2, N=72, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial
    17d
    The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery (clinicaltrials.gov)
    P3, N=101, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial primary completion date: Aug 2025 --> Dec 2025
    Trial primary completion date
    29d
    Coexistence of Immune Thrombocytopenic Purpura and Bernard-Soulier Syndrome: A Rare Pediatric Case Report. (PubMed, Int Med Case Rep J)
    She was managed with intravenous immunoglobulin (IVIG) and corticosteroids; Eltrombopag was discontinued due of leukemic risk...The purpose of this case report is to illustrate the diagnostic challenges and therapeutic considerations in children with coexisting acquired (ITP) and inherited (BSS) thrombocytopenias, particularly in the presence of a leukemogenic predisposition gene (ETV6). This case underscores the importance of comprehensive genetic evaluation in guiding individualized therapy and long-term surveillance.
    Journal
    |
    ETV6 (ETS Variant Transcription Factor 6)
    |
    Promacta (eltrombopag)
    1m
    A Multicenter, Prospective, Observational Study of Romiplostim N01 in Combination with Immunosuppressive Therapy (IST) for the Treatment of Aplastic Anemia (AA) (ChiCTR2500111349)
    P4, N=40, Not yet recruiting, The First Affiliated Hospital of Shandong First Medical University; The First Affiliated Hospital of Shandong First Medical University
    New P4 trial
    |
    Nplate (romiplostim)
    1m
    Single arm, prospective clinical study on the application of Haiqupopa ethanolamine tablets in the treatment of thrombocytopenia (CTIT) caused by tumor therapy (ChiCTR2500111291)
    P4, N=42, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New P4 trial
    1m
    Prospective, Single-Arm, Multicenter Clinical Study of Romiplostim N01 for the Treatment of Thrombocytopenia Induced by Concurrent Chemoradiotherapy in Solid Tumors (ChiCTR2500110699)
    P4, N=92, Not yet recruiting, Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute); Shandong First Medical University
    New P4 trial
    |
    Nplate (romiplostim)
    1m
    Study on the Efficacy and Safety of Romiplostim Injection N01 as Second-line Treatment for Thrombocytopenia Following Hematologic Malignancy Therapy (ChiCTR2500109111)
    P4, N=30, Not yet recruiting, First Affiliated Hospital of Kunming Medical University; First Affiliated Hospital of Kunming Medical University
    New P4 trial
    |
    Nplate (romiplostim)